دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Pandemic to endemic: optimising COVID-19 immunity
doi : 10.1016/S2665-9913(24)00005-5
Volume 6, Issue 2, February 2024, Page e63
Subclinical synovitis: let's discuss prognosis before treatment
Melek Yalcin-Mutlu a, Koray Tascilar a
doi : 10.1016/S2665-9913(23)00342-9
Volume 6, Issue 2, February 2024, Pages e64-e65
Targeting mTOR in sarcoid granulomas: where the rubber meets the road
Adam S Morgenthau a
doi : 10.1016/S2665-9913(23)00339-9
Volume 6, Issue 2, February 2024, Pages e65-e66
Improving COVID-19 vaccine response in individuals receiving methotrexate
Katie Bechman a, James Galloway a
doi : 10.1016/S2665-9913(23)00306-5
Volume 6, Issue 2, February 2024, Pages e67-e68
Association of economic insecurities with patient-reported outcomes in systemic lupus erythematosus
Ana Valle a, Candace H Feldman a
doi : 10.1016/S2665-9913(23)00323-5
Volume 6, Issue 2, February 2024, Pages e68-e70
Research in Brief
Jennifer Thorley
doi : 10.1016/S2665-9913(24)00004-3
Volume 6, Issue 2, February 2024, Page e71
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study
Leticia Garcia-Montoya MD a c d, Jing Kang PhD b, Laurence Duquenne MD a c, Andrea Di Matteo PhD a c, Jacqueline L Nam PhD a c, Kate Harnden MBChB a c, Rahaymin Chowdhury MBChB a c, Kulveer Mankia MD a c, Prof Paul Emery FMedSci a c
doi : 10.1016/S2665-9913(23)00305-3
Volume 6, Issue 2, February 2024, Pages e72-e80
Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial
Anna Redl MD a f, Konstantin Doberer MD b, Luisa Unterluggauer MD a, Lisa Kleissl MSc a f, Christoph Krall PhD c, Carolina Mayerhofer a, Bärbel Reininger Dipl Ing a, Victoria Stary MD d, Nina Zila MSc a g, Prof Wolfgang Weninger MD a, Prof Thomas Weichhart PhD e, Prof Christoph Bock PhD c f, Thomas Krausgruber PhD c f, Georg Stary MD a f
doi : 10.1016/S2665-9913(23)00302-8
Volume 6, Issue 2, February 2024, Pages e81-e91
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Prof Abhishek Abhishek PhD a, Nicholas Peckham MSc c d, Corinna Pade PhD e *, Joseph M Gibbons PhD e *, Lucy Cureton BSc c d, Anne Francis PhD c d, Vicki Barber PhD c d, Jennifer A E Williams PhD c d, Duncan Appelbe PhD c d, Lucy Eldridge BSc c d, Patrick Julier MSc c d, Prof Daniel M Altmann PhD f, James Bluett PhD h i, Tim Brooks FRC Path j, Laura C Coates PhD c k, Ines Rombach PhD l, Amanda Semper j, Ashley Otter PhD j, Prof Ana M Valdes PhD a, Prof Jonathan S Nguyen-Van-Tam DM b…Catrin Jones
doi : 10.1016/S2665-9913(23)00298-9
Volume 6, Issue 2, February 2024, Pages e92-e104
Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study
Donavon Sandoval-Heglund BA a *, Eric Roberts PhD b *, Joonsuk Park MS b, Maria Dall'Era MD b, Cristina Lanata MD c, Kamil E Barbour PhD d, Kurt J Greenlund PhD d, Caroline Gordon MD e, Prof Patricia P Katz PhD b f †, Prof Jinoos Yazdany MD MPH b â€
doi : 10.1016/S2665-9913(23)00296-5
Volume 6, Issue 2, February 2024, Pages e105-e114
Idiopathic inflammatory myopathies: current insights and future frontiers
Caoilfhionn M Connolly MD MSc a, Latika Gupta MD DM b c d, Manabu Fujimoto MD PhD e, Prof Pedro M Machado MD PhD f g h i, Julie J Paik MD MHS a
doi : 10.1016/S2665-9913(23)00322-3
Volume 6, Issue 2, February 2024, Pages e115-e127
Cardiac myxoma mimicking a spondyloarthritis flare
Anastasia Delmotte MD a b, Phalla Ou PhD a c, Ilyass Zouhry MD a d, Patrick Nataf PhD a e, Philippe Dieudé PhD a b
doi : 10.1016/S2665-9913(23)00093-0
Volume 6, Issue 2, February 2024, Page e128
